The deadline for submitting abstracts has been closed. Authors will receive a response on the evaluation of their work on or before 12 January 2018.
Thank you for your participation!
“Online abstract submission is now open!”.
- Abstracts describing original basic science and clinical work related to the broad area of rheumatic diseases may be submitted.
- An abstract is ineligible for consideration if:
- Reports work that has been accepted or published prior to ArLAR conference in a print or online journal.
- The abstract contains data that was presented at a scientific meeting more than 12 months earlier.
- Duplicate abstracts from the same study should not be submitted as multiple abstracts. Abstracts that appear as more than one version of a single study will be rejected.
- By submitting your abstract, you agree to present the abstract if it is selected for presentation during an oral or poster abstract presentation. If your abstract can only be presented as a poster, please report this during the submission process.
- Case reports are NOT considered appropriate and will not be reviewed, unless it is a rare case and no similar case reports were identified.
- If the abstract reports results of a clinical trial not yet approved by a regulatory agency, you will be required to identify the trial phase.
- Any work with human or animal subjects reported in submitted abstracts must comply with the guiding principles for experimental procedures found in the Declaration of Helsinki of the World Medical Association.
- Please disclose funding resources for this work, including governmental, pharmaceutical, etc. If funded by pharmaceutical company or biotech company then a statement must be added about the role of the study sponsor.
- The reviewers will judge the abstracts according to the scientific or clinical value, relevance to Arab world, suitability of methods to aims, conclusions confirmed by objective results, objectivity of statements, description of methods used, ethics, originality of work, standard of English and overall impression.
- For the young investigators abstracts, this is defined as abstracts submitted by residents, fellows on training or rheumatologists with < 6 year of independent clinical practice.
- The abstract limit is 300 words, which excludes the title, names of authors/co-authors, authors’ affiliation, spacing and disclosures. However, imported tables and graphics will decrease the character count by 25 words from the total limit allow Abstracts exceeding the character limit will be considered “incomplete”. Abstracts marked “incomplete” at the close of the submission deadline will be ineligible for consideration.
- Please ensure that your abstract does not contain spelling, grammatical or scientific errors, as it will be reproduced, if accepted, exactly as submitted. No proofreading will be done.
- Please refrain from using acronyms in your abstract titles. Acronyms may remain in the body of the abstract and in the author lis
- Omit all names and geographical references in the body of the abstr Organize content as follows:
- Background: Background or Statement of Purpose
- Methods: Methods, materials and analytical procedure used
- Results: Summary of the results in sufficient detail to support conclusion
- Conclusion: Conclusions reached (do not state “results will be discussed”)
The abstracts are subdivided into categories and topics. The correct category and topic must be selected to ensure correct scoring. The content of the abstract must be topic related.1. Basic and translational research
- Genomics, genetic basis of disease and HLA/T cell recognition
- Adaptive immunity (T cells and B cells) in rheumatic diseases
- Innate immunity in rheumatic diseases
- Cytokines and inflammatory mediators
- Cartilage, synovium and osteoimmunology
- Rheumatoid arthritis – etiology, pathogenesis and animal models
- Spondyloarthritis – etiology, pathogenesis and animal models
- SLE, Sjögren’s and APS – etiology, pathogenesis and animal models
- Scleroderma, myosotis and related syndromes – etiology, pathogenesis and animal models
- Basic science in paediatric rheumatology
- Rheumatoid arthritis – prognosis, predictors and outcome
- Rheumatoid arthritis – comorbidity and clinical aspects
- Rheumatoid arthritis – anti-TNF therapy
- Rheumatoid arthritis – other biologic treatment
- Rheumatoid arthritis – non biologic treatment
- SLE, Sjögren’s and APS – treatment
- SLE, Sjögren’s and APS – clinical aspects (other than treatment)
- Scleroderma, myositis and related syndromes
- Spondylarthropathies – treatment
- Spondylarthropathies – clinical aspects (other than treatment)
- Psoriatic arthritis
- Crystal diseases, metabolic bone diseases and bone diseases other than osteoporosis
- Infection-related rheumatic diseases
- Back pain, mechanical musculoskeletal problems, local soft tissue disorders
- Paediatric rheumatology
- Other orphan diseases
- Diagnostics and imaging procedures
- Epidemiology, health services and outcome research
The deadline for abstract submission is 15 December 2017. Any abstract submitted after the deadline will not be reviewed.
No fees for processing the abstract.
All authors must disclose any relevant financial relationship(s) at the time of abstract submission. Examples include, but are not limited to:
- None: has no relevant financial relationship to disclose
- Stock options or bond holdings in a for-profit corporation or self-directed pension plan
- Research grants
- Employment (full or part-time)
- Ownership or partnership
- Consulting fees or other remuneration
- Non-remunerative positions of influence such as officer, board member, trustee or public spokesperson
- Speakers’ bureau
Disclosures collected at the time of submission will be published in the scientific program, abstract supplement and on the ARLAR website. Abstracts will not be accepted without proper completion of the conflict of interest/disclosure section on the abstract submission form. The abstract review process is blinded; therefore, the disclosure information you provide will not influence the review of your abstract.
- After the submission deadline, completed abstracts will be peer-reviewed. “Incomplete” abstracts will not be considered. To ensure the integrity of the review process, revisions to abstracts will not be accepted after the submission deadline – no exceptions.
- Abstracts will be peer-reviewed by a minimum of two members of scientific committee, according to subject categories. All reviewers are required to sign a confidentiality agreement.
- All abstracts will be reviewed without knowledge of the author(s), institution(s) or disclosure information.
- Accepted abstracts will be selected as either a short oral presentation or a poster presentation.
The presenting author is the only author who will receive notification and is the point of contact for all co-authors. Presenting authors will be notified by the beginning of January 2018 and are responsible for notifying all abstract co-authors.